Epoprostenol: Flushing or Erythroderma?

Epoprostenol: Flushing or Erythroderma?

Vol. 25, No. 2, 2013 271 Received December 27, 2011, Revised July 31, 2012, Accepted for publication September 19, 2012 Corresponding author: María Luisa Martínez-Martínez, Department of Dermatology, University General Hospital of Albacete, falcó brothers, No. 37, 02006, Albacete, Spain. Tel: 34-967-59-71-00, Fax: 34-697-24-39-52, E-mail: mlmartinezm@ sescam.jccm.es This is an Open Access artic...

erythroderma . Myelodysplasia presenting as

Cutaneous manifestations of haematological malignancies, although well recognized in acute monoblastic leukaemia and lymphoma, are relatively uncommon in primary myelodysplastic syndrome (MDS), which is a group of heterogeneous disorders formerly known as pre-leukaemia. Previously reported cases of skin involvement in this syndrome have been confined to a sub-type of MDS, namely chronic myelomo...

Non-bullous congenital ichthyosiform erythroderma.

A 4-day-old neonate was brought with complaints of fissuring and peeling of skin involving almost the whole body. The neonate had generalized desquamation not even sparing the palms, soles and face. The parents informed that the baby was born, enclosed in a constricting parchmentlike membrane (collodion baby) that had gradually comeoff. There was a past history of a child born with similar pres...

Inhaled epoprostenol in ARDS.

ARDS presents as a devastating entity characterized by severe hypoxemia, systemic inflammatory response, and high hospital mortality ( 30%).1 Despite years of research, the utilization of mechanical ventilation with low tidal volumes (6 mL/kg of ideal body weight) remains the only therapy that shows reduction in mortality in all severity groups.2 Systemic inflammation with subsequent multiorgan...

Congenital reticular ichthyosiform erythroderma.